Hydroxyurea treatment for chronic myeloid leukemia during pregnancy
ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, vol.79, no.9, pp.803-804, 2000 (SCI-Expanded, Scopus)
- Publication Type: Article / Article
- Volume: 79 Issue: 9
- Publication Date: 2000
- Doi Number: 10.1034/j.1600-0412.2000.079009803.x
- Journal Name: ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA
- Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Page Numbers: pp.803-804
- Keywords: chronic myeloid leukemia, hydroxurea treatment, white blood cell count
- Dokuz Eylül University Affiliated: Yes
Abstract
The incidence of chronic myeloid leukemia (CML) associated with pregnancy is estimated to be 1/75,000. Several types of treatments have been used for CML during pregnancy. These are cytotoxic drugs, alpha-interferone, splenic irradiation (with shielding of the uterus) and leukapheresis. Hydroxyurea is a cytotoxic drug that inhibits the synthesis of DNA and can be used both in the chronic and accelerated phases of CML (1).